Antibe Therapeutics Inc.

Versiunea din 18 septembrie 2024 13:55, autor: Admin (discuție | contribuții) (Pagină nouă: Pagina dedicata companiei Antibe Therapeutics Inc. listata cu simbolul CA.ATE ==Descriere companie== Antibe Therapeutics Inc. (http://www.antibethera.com/) is a commercial-stage pharmaceutical company. The Company is focused on pain, inflammation, and regenerative medicine. The Company’s products pipeline includes Otenaproxesul, ATB-352, and ATB-340. Otenaproxesul is a novel anti-inflammatory drug that releases hydrogen sulfide and combines hydrogen sulfide with naproxen,...)
(dif) ← Versiunea anterioară | Versiunea curentă (dif) | Versiunea următoare → (dif)

Pagina dedicata companiei Antibe Therapeutics Inc. listata cu simbolul CA.ATE

Descriere companie

Antibe Therapeutics Inc. (http://www.antibethera.com/) is a commercial-stage pharmaceutical company. The Company is focused on pain, inflammation, and regenerative medicine. The Company’s products pipeline includes Otenaproxesul, ATB-352, and ATB-340. Otenaproxesul is a novel anti-inflammatory drug that releases hydrogen sulfide and combines hydrogen sulfide with naproxen, non-steroidal, anti-inflammatory drug. ATB-352 is a hydrogen sulfide-releasing derivative of ketoprofen. ATB-340 is a gastrointestinal-safe version of low-dose aspirin for cardiovascular and cancer protection. The Company, through its wholly owned subsidiary, Citagenix Inc. (Citagenix) is a seller of tissue regenerative products servicing the orthopaedic and dental marketplaces. Citagenix’s portfolio consists of branded biologics and medical devices that promote bone regeneration.

Grafic actiuni companie

Ultimele stiri despre Antibe Therapeutics Inc. (CA.ATE)